TickerKhojPharmaceuticals · Pharmaceuticals: Other · NSE: SATKARTAR · data 2026-11-01
Sat Kartar Life Limited
In plain words
Price: 40.9% below its 52-week high of ₹219.8.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹225 cr |
| Net profit (last 12 months) | ₹19 cr |
| Sales growth, 3 years (yearly) | 34.2% |
| Profit growth, 3 years (yearly) | 89.7% |
At a glance
P/E 10.7, P/B 2.4, dividend yield 0.5%. Price relative to earnings and book value (low is cheaper, not better).
ROE 28.7%, ROCE 34.8%, operating margin 11.1%: how much profit it earns on the money it uses.
Debt/equity 0.04, Profit growth 89.7% and sales growth 34.2% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Virtually debt-free (debt/equity 0.1 or less).
- High return on equity (28.7%).
- Profit grew 89.7% a year over 3 years.
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
5/100 · Weak over the last ~60 sessions
- Delivery vs usual 0/30: No stored daily delivery history for this stock (0 points).
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Common questions
Is Sat Kartar Life Limited debt-free?
Its latest reported debt-to-equity ratio is 0.04, which is very low.
What is Sat Kartar Life Limited's P/E ratio?
About 10.7, based on the last 12 months' earnings and a price of ₹130 (data 2026-11-01).
What is the 52-week high and low of Sat Kartar Life Limited?
The 52-week high is ₹219.8 and the 52-week low is ₹110.3.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Sat Kartar Life Limited | ₹130 | ₹205 cr | 10.7 | 2.4 | 28.7% | 34.8% | 0.04 | -28.2% |
| Amrutanjan Health Care Limited | ₹496.65 | ₹1,452 cr | 26.6 | — | 16.6% | 17.9% | 0 | -33.0% |
| Shri Ahimsa Naturals Limited | ₹399.9 | ₹952 cr | 32.1 | 4.8 | 16.7% | 18.4% | 0.1 | +55.0% |
| Influx Healthtech Limited | ₹264.5 | ₹612 cr | 28.3 | — | 30% | 38% | — | +48.4% |
| Lyka Labs Limited | ₹76.6 | ₹278 cr | — | 2.9 | -10.2% | -9.9% | 0.53 | -20.6% |
| Natural Capsules Limited | ₹138.06 | ₹142 cr | — | — | -7.5% | -6.4% | 0.52 | -33.0% |
Compare SATKARTAR with AMRUTANJAN in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open SATKARTAR in TickerKhoj →